Last reviewed · How we verify

Infusional 5-Fluorouracil

Italian Trial in Medical Oncology · Phase 2 active Small molecule Under review Quality 0/100

Infusional 5-Fluorouracil is a Pyrimidine analog Small molecule drug developed by Italian Trial in Medical Oncology. It is currently in Phase 2 development for Colorectal cancer. Also known as: Adrucil, Efudex, Fluoroplex.

Inhibits thymidylate synthase

Infusional 5-Fluorouracil is used to treat various types of cancer, including colorectal cancer, gastroesophageal junction adenocarcinoma, colon cancer, stomach neoplasm, and metastatic cancer. It works by inhibiting the enzyme thymidylate synthase, which is involved in DNA synthesis.

Likelihood of approval
13.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Oncology Phase 2 attrition -2.0pp
    Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameInfusional 5-Fluorouracil
Also known asAdrucil, Efudex, Fluoroplex
SponsorItalian Trial in Medical Oncology
Drug classPyrimidine analog
TargetThymidylate synthase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

5-Fluorouracil works by inhibiting thymidylate synthase, an enzyme involved in DNA synthesis, thereby preventing cancer cell growth.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Infusional 5-Fluorouracil

What is Infusional 5-Fluorouracil?

Infusional 5-Fluorouracil is a Pyrimidine analog drug developed by Italian Trial in Medical Oncology, indicated for Colorectal cancer.

How does Infusional 5-Fluorouracil work?

Inhibits thymidylate synthase

What is Infusional 5-Fluorouracil used for?

Infusional 5-Fluorouracil is indicated for Colorectal cancer.

Who makes Infusional 5-Fluorouracil?

Infusional 5-Fluorouracil is developed by Italian Trial in Medical Oncology (see full Italian Trial in Medical Oncology pipeline at /company/italian-trial-in-medical-oncology).

Is Infusional 5-Fluorouracil also known as anything else?

Infusional 5-Fluorouracil is also known as Adrucil, Efudex, Fluoroplex.

What drug class is Infusional 5-Fluorouracil in?

Infusional 5-Fluorouracil belongs to the Pyrimidine analog class. See all Pyrimidine analog drugs at /class/pyrimidine-analog.

What development phase is Infusional 5-Fluorouracil in?

Infusional 5-Fluorouracil is in Phase 2.

What are the side effects of Infusional 5-Fluorouracil?

Common side effects of Infusional 5-Fluorouracil include Hand-foot syndrome, Diarrhea, Mucositis.

What does Infusional 5-Fluorouracil target?

Infusional 5-Fluorouracil targets Thymidylate synthase and is a Pyrimidine analog.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing